NVDA
NVIDIA
112.690 TSLA
Tesla
262.670 PLTR
Palantir
84.910 AVGO
Broadcom
194.960 GRRR
Gorilla Technology
28.410 
🟣 Watchlist, JANUARY 31,2025, Friday. NFA.
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t appreciate my watchlist, STAY AWAY and I won’t think twice blocking you. I shun uncouth and toxic people in my life.
🟣- My Top Picks
🟣🟣- My Mega Top Pick/s
AGAIN, NEVER OPEN A POSITION WITHOUT ANALYZING CHART, INDICATORS, ORDER BOOK, SHORTS AVAILABILITY
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
NEWS JAN 30
$Benson Hill (BHIL.US)$ 🟣PR 1/30 announced positive results from a controlled broiler feeding trial conducted with Tyson Foods, validating their Ultra-High Protein, Low-Oligosaccharide (UHP-LO) soybean meal as a cost-effective alternative to conventional soybean meal in poultry nutrition. Low float. 0 shares LTB. No cash on hand. Ran but still has good volume AH.
$Cognition Therapeutics (CGTX.US)$ PR 1/30 Positive Phase 2 Study of Zervimesine in Dementia with Lewy Bodies (DLB). Findings: Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI A-L), 52% on activities of daily living, 91% on cognitive fluctuations, 62% on motor symptoms compared to placebo. COH $12.9M good for 5.8 months
$Cipher Mining (CIFR.US)$ PR AH 1/30 Announces $50 Million PIPE Investment from SoftBank Group. This involves SoftBank purchasing approximately 10.4 million shares of Cipher common stock. With this, there will be dilution as SoftBank will buy newly issued 10.4M shares. This will only go up based on market sentiment but not on the core content of the news (dilution)
$Envirotech Vehicles (EVTV.US)$ 🟣PR AH 1/30 Envirotech Vehicles Withdraws April 2024 Filing for Stock Offering. This may imply they are expecting capital infusion not to see the need of an offering/dilution. Low float. 0 shares LTB. COH $1.4M good for 4.4 months. You see they don’t have much COH but withdrew offering .
$Foremost Lithium Resource & Technology (FMST.US)$ 🟣🟣PR AH 1/30 announced that the effective date of its spin-out of gold and silver properties into a new company, to January 31, 2025, at 12:01 a.m. PT (3AM ET). Shareholders holding Foremost shares as of January 30, 2025, will receive one new Foremost common share and two Rio Grande common shares for each Foremost share held. This spinoff involves FMST concentrating its operations on lithium and uranium whereas Rio will be focused on gold and silver. Low float. 0 shares LTB. COH $4.7M good for 35.8 months
$Genfit (GNFT.US)$ 🟣PR AH 1/30 6K filed. Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan: GNFT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital. 130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestones. This financing extends cash runway to 2027. COH $72M good for 10 months
$Nauticus Robotics (KITT.US)$ 🟣🟣PR AH 1/30 Leidos And Nauticus Robotics Enter Alliance To Advance Subsea Autonomy Solutions. The alliance aims to combine the companies' complementary expertise to develop next-generation autonomous underwater systems capable of tackling increasingly complex missions.
$Koss Corp (KOSS.US)$ PR AH 1/30 Fair ER: Net sales 5.9% increased YoY; Net income $94,142 compared to a net loss of $269,153 for the second quarter of the prior fiscal year; diluted net income per common share 0.01 vs 0.03. It may go up but don’t expect to skyrocket based on ER unless there is much market sentiment . Low float. COH $200K. High risk for dilution.
$Snow Lake Resources (LITM.US)$ PR 1/30 announces its strong financial position entering 2025, having raised over $35 million in the past two months to advance its uranium and lithium projects while exploring nuclear energy opportunities. SI 21%. COH $38.3M
$Comstock Inc (LODE.US)$ 🟣PR AH 1/30 Comstock Fuels and SACL Execute Definitive Exclusive Commercial Agreements.
Under the terms of agreement, LODE will contribute site specific technology rights in exchange for a 20% equity stake in each Bioleum Refinery, plus a royalty fee equal to 6% of each refinery's sales of licensed products, and engineering fees equal to 6% of total construction costs. COH $23.8M good for 24 months
$Safe Pro Group (SPAI.US)$ 🟣PR 1/30 Enters Multi-Year Agreement for its Patented Drone AI Demining Platform with Ukraine's Leading Grain Export and Agricultural Organization NIBULON Ltd. Low float. COH $900K good for 2.8 months
$Valneva (VALN.US)$ PR 1/30 Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million - Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®. No dilution risk.
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
PREVIOUS DAYS’ NEWS
$Adial Pharmaceuticals (ADIL.US)$ PR 1/29 Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder. Adial's formulation exhibited predictable bioavailability relative to the reference standard; near-micro doses exhibited dose proportionality in pharmacokinetic exposure, and no food effect. Safety and tolerability consistent with ondansetron's extensive human use experience. COH $3.8M good for 6.3 months
$ATAI Life Sciences (ATAI.US)$ PR 1/28 Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder. Study showed sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months. COH $113M
$Alterity Therapeutics (ATHE.US)$ PR AH 1/29 announced positive topline results from its Phase 2 clinical trial of ATH434 in early-stage Multiple System Atrophy (MSA). The trial demonstrated that ATH434 significantly slowed disease progression, with up to a 48% reduction in clinical decline as measured by the Unified MSA Rating Scale (UMSARS) Part I. Additionally, MRI biomarkers indicated stabilization of iron levels in brain regions affected by MSA. ATH434 was well-tolerated, with a favorable safety profile. These findings suggest that ATH434 may offer a disease-modifying treatment option for individuals with MSA. COH $5.06M good for 3 months. Low float. May still gain steam. 0 shares LTB. This didn’t soar during RTH as 58% was diverted to dark pool.
$Knightscope (KSCP.US)$ PR 1/28 Partners with U.S. Air Force on Autonomous Security Robots. It is a Phase I SBIR contract to streamline and improve Air Force Installation Security procedures and outcomes. Low float. COH $8.9M good for 4.6 months
$Lisata Therapeutics (LSTA.US)$ PR 1/23 same as 1/22 PR 1/22 Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma. Study showed 4 CR (complete response- non detectable) is impressive considering this is a very aggressive and deadly cancer. Positive overall survival which is one of the most important metric in trials. It’s badly beaten by shorts. May rebound. Low float. COH $29.5M good for 17.9 months.
$Mobilicom (MOB.US)$ PR 1/28 Mobilicom's Cybersecure MCU-30 Selected by One of the World's Largest Loitering Munitions Manufacturers (Tier-1 Israel-based defense company) for its Latest Perimeter Protection Drone Fleets. Low float. COH $11.2M good for 24 months
$OS Therapies (OSTX.US)$ PR 1/29 Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline. This eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications. Low float. COH $6.7M good for 12 months
$Telomir Pharmaceuticals (TELO.US)$ PR 1/28 Announces Breakthrough Results With Telomir-1 showing it fully reverses Copper-Induced oxidative stress in human cell lines. in Human Cell Lines. Note why this is important: Oxidative stress drives aging and is a key factor in diseases like Alzheimer’s, age-related macular degeneration, cardiovascular diseases, cancer, and diabetes. Low float. No cash on hand. High risk.
$Zentalis Pharmaceuticals (ZNTL.US)$ PR 1/29 Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer: Objective Response Rate (ORR) of approximately 35% in response-evaluable patients, median duration of response of approximately 5.5 months with with no new safety concerns identified. For platinum resistant ovarian cancer, 35% ORR is good. For information purposes, “Resistant” means a lot of treatment option failed or does not respond to treatment which makes 35% ORR good. Plummeted but may get an “awakening” rebound. COH $335M
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
POSSIBLE MOMENTUM PLAYS
$Aclarion (ACON.US)$
$BloomZ (BLMZ.US)$
$BTC Digital (BTCT.US)$
$China Liberal Education (CLEU.US)$
$Context Therapeutics (CNTX.US)$
$Cyclerion Therapeutics (CYCN.US)$
$Digihost Technology (DGHI.US)$
$Dominari Holdings (DOMH.US)$
$Impact BioMedical (IBO.US)$
$Sacks Parente Golf (SPGC.US)$
$Trident Digital Tech (TDTH.US)$
$X4 Pharmaceuticals (XFOR.US)$
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t appreciate my watchlist, STAY AWAY and I won’t think twice blocking you. I shun uncouth and toxic people in my life.
🟣- My Top Picks
🟣🟣- My Mega Top Pick/s
AGAIN, NEVER OPEN A POSITION WITHOUT ANALYZING CHART, INDICATORS, ORDER BOOK, SHORTS AVAILABILITY
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
NEWS JAN 30
$Benson Hill (BHIL.US)$ 🟣PR 1/30 announced positive results from a controlled broiler feeding trial conducted with Tyson Foods, validating their Ultra-High Protein, Low-Oligosaccharide (UHP-LO) soybean meal as a cost-effective alternative to conventional soybean meal in poultry nutrition. Low float. 0 shares LTB. No cash on hand. Ran but still has good volume AH.
$Cognition Therapeutics (CGTX.US)$ PR 1/30 Positive Phase 2 Study of Zervimesine in Dementia with Lewy Bodies (DLB). Findings: Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI A-L), 52% on activities of daily living, 91% on cognitive fluctuations, 62% on motor symptoms compared to placebo. COH $12.9M good for 5.8 months
$Cipher Mining (CIFR.US)$ PR AH 1/30 Announces $50 Million PIPE Investment from SoftBank Group. This involves SoftBank purchasing approximately 10.4 million shares of Cipher common stock. With this, there will be dilution as SoftBank will buy newly issued 10.4M shares. This will only go up based on market sentiment but not on the core content of the news (dilution)
$Envirotech Vehicles (EVTV.US)$ 🟣PR AH 1/30 Envirotech Vehicles Withdraws April 2024 Filing for Stock Offering. This may imply they are expecting capital infusion not to see the need of an offering/dilution. Low float. 0 shares LTB. COH $1.4M good for 4.4 months. You see they don’t have much COH but withdrew offering .
$Foremost Lithium Resource & Technology (FMST.US)$ 🟣🟣PR AH 1/30 announced that the effective date of its spin-out of gold and silver properties into a new company, to January 31, 2025, at 12:01 a.m. PT (3AM ET). Shareholders holding Foremost shares as of January 30, 2025, will receive one new Foremost common share and two Rio Grande common shares for each Foremost share held. This spinoff involves FMST concentrating its operations on lithium and uranium whereas Rio will be focused on gold and silver. Low float. 0 shares LTB. COH $4.7M good for 35.8 months
$Genfit (GNFT.US)$ 🟣PR AH 1/30 6K filed. Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan: GNFT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital. 130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestones. This financing extends cash runway to 2027. COH $72M good for 10 months
$Nauticus Robotics (KITT.US)$ 🟣🟣PR AH 1/30 Leidos And Nauticus Robotics Enter Alliance To Advance Subsea Autonomy Solutions. The alliance aims to combine the companies' complementary expertise to develop next-generation autonomous underwater systems capable of tackling increasingly complex missions.
$Koss Corp (KOSS.US)$ PR AH 1/30 Fair ER: Net sales 5.9% increased YoY; Net income $94,142 compared to a net loss of $269,153 for the second quarter of the prior fiscal year; diluted net income per common share 0.01 vs 0.03. It may go up but don’t expect to skyrocket based on ER unless there is much market sentiment . Low float. COH $200K. High risk for dilution.
$Snow Lake Resources (LITM.US)$ PR 1/30 announces its strong financial position entering 2025, having raised over $35 million in the past two months to advance its uranium and lithium projects while exploring nuclear energy opportunities. SI 21%. COH $38.3M
$Comstock Inc (LODE.US)$ 🟣PR AH 1/30 Comstock Fuels and SACL Execute Definitive Exclusive Commercial Agreements.
Under the terms of agreement, LODE will contribute site specific technology rights in exchange for a 20% equity stake in each Bioleum Refinery, plus a royalty fee equal to 6% of each refinery's sales of licensed products, and engineering fees equal to 6% of total construction costs. COH $23.8M good for 24 months
$Safe Pro Group (SPAI.US)$ 🟣PR 1/30 Enters Multi-Year Agreement for its Patented Drone AI Demining Platform with Ukraine's Leading Grain Export and Agricultural Organization NIBULON Ltd. Low float. COH $900K good for 2.8 months
$Valneva (VALN.US)$ PR 1/30 Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million - Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®. No dilution risk.
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
PREVIOUS DAYS’ NEWS
$Adial Pharmaceuticals (ADIL.US)$ PR 1/29 Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder. Adial's formulation exhibited predictable bioavailability relative to the reference standard; near-micro doses exhibited dose proportionality in pharmacokinetic exposure, and no food effect. Safety and tolerability consistent with ondansetron's extensive human use experience. COH $3.8M good for 6.3 months
$ATAI Life Sciences (ATAI.US)$ PR 1/28 Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder. Study showed sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months. COH $113M
$Alterity Therapeutics (ATHE.US)$ PR AH 1/29 announced positive topline results from its Phase 2 clinical trial of ATH434 in early-stage Multiple System Atrophy (MSA). The trial demonstrated that ATH434 significantly slowed disease progression, with up to a 48% reduction in clinical decline as measured by the Unified MSA Rating Scale (UMSARS) Part I. Additionally, MRI biomarkers indicated stabilization of iron levels in brain regions affected by MSA. ATH434 was well-tolerated, with a favorable safety profile. These findings suggest that ATH434 may offer a disease-modifying treatment option for individuals with MSA. COH $5.06M good for 3 months. Low float. May still gain steam. 0 shares LTB. This didn’t soar during RTH as 58% was diverted to dark pool.
$Knightscope (KSCP.US)$ PR 1/28 Partners with U.S. Air Force on Autonomous Security Robots. It is a Phase I SBIR contract to streamline and improve Air Force Installation Security procedures and outcomes. Low float. COH $8.9M good for 4.6 months
$Lisata Therapeutics (LSTA.US)$ PR 1/23 same as 1/22 PR 1/22 Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma. Study showed 4 CR (complete response- non detectable) is impressive considering this is a very aggressive and deadly cancer. Positive overall survival which is one of the most important metric in trials. It’s badly beaten by shorts. May rebound. Low float. COH $29.5M good for 17.9 months.
$Mobilicom (MOB.US)$ PR 1/28 Mobilicom's Cybersecure MCU-30 Selected by One of the World's Largest Loitering Munitions Manufacturers (Tier-1 Israel-based defense company) for its Latest Perimeter Protection Drone Fleets. Low float. COH $11.2M good for 24 months
$OS Therapies (OSTX.US)$ PR 1/29 Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline. This eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications. Low float. COH $6.7M good for 12 months
$Telomir Pharmaceuticals (TELO.US)$ PR 1/28 Announces Breakthrough Results With Telomir-1 showing it fully reverses Copper-Induced oxidative stress in human cell lines. in Human Cell Lines. Note why this is important: Oxidative stress drives aging and is a key factor in diseases like Alzheimer’s, age-related macular degeneration, cardiovascular diseases, cancer, and diabetes. Low float. No cash on hand. High risk.
$Zentalis Pharmaceuticals (ZNTL.US)$ PR 1/29 Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer: Objective Response Rate (ORR) of approximately 35% in response-evaluable patients, median duration of response of approximately 5.5 months with with no new safety concerns identified. For platinum resistant ovarian cancer, 35% ORR is good. For information purposes, “Resistant” means a lot of treatment option failed or does not respond to treatment which makes 35% ORR good. Plummeted but may get an “awakening” rebound. COH $335M
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
POSSIBLE MOMENTUM PLAYS
$Aclarion (ACON.US)$
$BloomZ (BLMZ.US)$
$BTC Digital (BTCT.US)$
$China Liberal Education (CLEU.US)$
$Context Therapeutics (CNTX.US)$
$Cyclerion Therapeutics (CYCN.US)$
$Digihost Technology (DGHI.US)$
$Dominari Holdings (DOMH.US)$
$Impact BioMedical (IBO.US)$
$Sacks Parente Golf (SPGC.US)$
$Trident Digital Tech (TDTH.US)$
$X4 Pharmaceuticals (XFOR.US)$
$Zapp Electric Vehicles (ZAPP.US)$
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
POSSIBLE SQUEEZE UNTIL FEBRUARY 7
$AquaBounty (AQB.US)$
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
POSSIBLE SQUEEZE UNTIL FEBRUARY 7
$AquaBounty (AQB.US)$
$Wah Fu Education (WAFU.US)$
$Exicure (XCUR.US)$
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
RS JAN 31
$ZK International (ZKIN.US)$ ~4M
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
POST RS SPLIT FOR POSSIBLE SPIKE
$BriaCell Therapeutics (BCTX.US)$
$Bionano Genomics (BNGO.US)$
$Wheeler Real Estate Investment Trust Inc (WHLR.US)$
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
FORM 4s, 13G, 13D
$AIM ImmunoTech (AIM.US)$ 1/21 Form 4 Code P Insider buy. COH $2.6M good for 2.1 months
$Ardelyx (ARDX.US)$ 1/22 Form 4 insider buy
$Assembly Biosciences (ASMB.US)$ 12/31 Form 4 insider buying. Low float. COH $97.6M good for 17.3 months.
$180 Life Sciences (ATNF.US)$ 1/3 13G 4.99. Low float.
$Chijet Motor (CJET.US)$ 1/21 13G 8.72%. No cash on hand.
$Cellectis (CLLS.US)$ 1/24 13D/A 44% up from 22% Astra Zeneca
$KALA BIO (KALA.US)$ 12/31 Form 4 huge insider buying. Low float.
$NAYA Biosciences (NAYA.US)$ 1/16 16 13Gs 9.99% and 6.9%. Low float.
$Outlook Therapeutics (OTLK.US)$ 1/22 13D/A 38.6% ownership up from 25%
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
STOCK EDUCATION
$Exicure (XCUR.US)$
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
RS JAN 31
$ZK International (ZKIN.US)$ ~4M
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
POST RS SPLIT FOR POSSIBLE SPIKE
$BriaCell Therapeutics (BCTX.US)$
$Bionano Genomics (BNGO.US)$
$Wheeler Real Estate Investment Trust Inc (WHLR.US)$
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
FORM 4s, 13G, 13D
$AIM ImmunoTech (AIM.US)$ 1/21 Form 4 Code P Insider buy. COH $2.6M good for 2.1 months
$Ardelyx (ARDX.US)$ 1/22 Form 4 insider buy
$Assembly Biosciences (ASMB.US)$ 12/31 Form 4 insider buying. Low float. COH $97.6M good for 17.3 months.
$180 Life Sciences (ATNF.US)$ 1/3 13G 4.99. Low float.
$Chijet Motor (CJET.US)$ 1/21 13G 8.72%. No cash on hand.
$Cellectis (CLLS.US)$ 1/24 13D/A 44% up from 22% Astra Zeneca
$KALA BIO (KALA.US)$ 12/31 Form 4 huge insider buying. Low float.
$NAYA Biosciences (NAYA.US)$ 1/16 16 13Gs 9.99% and 6.9%. Low float.
$Outlook Therapeutics (OTLK.US)$ 1/22 13D/A 38.6% ownership up from 25%
▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
STOCK EDUCATION
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Golden Goose : How do you think Trumps new tarrifs on Canada will affect FMST?
Lynn953818 : thank you very much
Jaguar8 OP Golden Goose : Since the U.S. imports lithium from Canada, any tariffs imposed would likely be reflected in one of two ways: either the cost is added to the price of lithium when it leaves Canada, or U.S. companies importing it will absorb the expense. While tariffs generate revenue for the government, the added costs will ultimately trickle down to consumer goods in the U.S. It’s important to note that Canada supplies 56% of the lithium used in the U.S. This means products that rely on lithium—such as batteries and certain pharmaceuticals—could see price increases if tariffs are applied.
Golden Goose Jaguar8 OP : thanks dude
TerryJinn : QSI, please give me a little push
Pablovski : the weekly and daily chart for $Alterity Therapeutics (ATHE.US)$ looks very nice. Maybe the analyst’s target isnt so absurd.